lenabasum (ajulemic acid)

a CB2 cannabinoid receptor agonist; structure in first source

Also Known As:

ajulemic acid; (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,8,10a-tetrahydro-6H-benzo(c)chromene-9-carboxylic acid; IP 751; IP-751; resunab; 6H-Dibenzo(b,d)pyran-9-carboxylic acid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-

Networked: 34 relevant articles (6 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Cannabinoids: 5901
      - Dronabinol: 2316
        lenabasum: 34

Experts

1.	Zurier, Robert B: 9 articles (05/2009 - 02/2003)
2.	White, Barbara: 6 articles (10/2022 - 01/2020)
3.	Rossetti, Ronald G: 6 articles (05/2009 - 02/2003)
4.	Dgetluck, Nancy: 4 articles (10/2022 - 01/2020)
5.	Burstein, Sumner: 4 articles (01/2021 - 08/2003)
6.	Burstein, Sumner H: 4 articles (01/2018 - 02/2003)
7.	Constantine, Scott: 3 articles (10/2022 - 01/2020)
8.	Karst, Matthias: 3 articles (06/2014 - 06/2005)
9.	Stebulis, Judith A: 3 articles (05/2009 - 01/2007)
10.	Bashir, Muhammad M: 2 articles (10/2022 - 01/2022)

Related Diseases

1.	Dermatomyositis (Dermatopolymyositis) 10/01/2022 - "Lenabasum treatment was well tolerated and was associated with greater improvement in Cutaneous Dermatomyositis Disease Area and Severity Index activity and multiple efficacy outcomes. " 10/01/2022 - "The objective of this study was to evaluate the safety and efficacy of lenabasum in patients with refractory cutaneous dermatomyositis. " 10/01/2022 - "The adjusted least-squares mean for Cutaneous Dermatomyositis Disease Area and Severity Index activity decreased more for lenabasum, and the difference was significant on day 113 (least-squares mean [standard error] difference = ‒6.5 [3.1], P = 0.038). " 12/01/2023 - "Data analyzed from the lenabasum phase 3 trial in DM showed that improvement in Cutaneous Dermatomyositis Disease Area and Severity Index Activity score increased proportionately with the degree of patient- or physician-reported improvement in skin disease, consistently measuring improvement when clinically meaningful improvement was reported at weeks 16-52. " 12/01/2023 - "Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial."
2.	Skin Diseases (Skin Disease) 12/01/2023 - "Data analyzed from the lenabasum phase 3 trial in DM showed that improvement in Cutaneous Dermatomyositis Disease Area and Severity Index Activity score increased proportionately with the degree of patient- or physician-reported improvement in skin disease, consistently measuring improvement when clinically meaningful improvement was reported at weeks 16-52. " 12/01/2023 - "Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial." 01/01/2020 - "Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis." 10/01/2022 - "Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial."
3.	Neuralgia (Stump Neuralgia) 04/01/2009 - "As we hypothesised that additional non-CB receptor mechanisms of ajulemic acid might contribute to its effect in neuropathic pain, we investigated the interaction of ajulemic acid with strychnine-sensitive alpha(1)- and alpha(1)beta-glycine receptors by using the whole-cell patch clamp technique. " 07/01/2005 - "CT-3 (ajulemic acid) is a synthetic analogue of a metabolite of Delta9-tetrahydrocannabinol that has reported analgesic efficacy in neuropathic pain states in man. " 06/01/2014 - "The synthetic cannabinoid ajulemic acid has been demonstrated to alleviate pain in patients suffering from chronic neuropathic pain. " 06/01/2014 - "Finally, we found that low concentrations of ajulemic acid efficiently inhibited Navβ4 peptide-mediated resurgent currents in Nav1.5. Our data suggest that block of sodium channels can be a relevant mechanism by which ajulemic acid alleviates neuropathic pain. " 04/01/2009 - "The synthetic cannabinoid ajulemic acid (CT-3) is a potent cannabinoid receptor agonist which was found to reduce pain scores in neuropathic pain patients in the absence of cannabis-like psychotropic adverse effects. "
4.	Diffuse Scleroderma (Progressive Systemic Sclerosis) 01/01/2020 - "Compared to placebo, lenabasum treatment was associated with greater improvement in the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score and other efficacy outcome measures that assessed overall disease, skin involvement, and patient-reported function. " 01/01/2020 - "To assess the safety and efficacy of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc). " 07/01/2021 - "A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale." 01/01/2020 - "Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis." 01/01/2023 - "This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc). "
5.	Inflammation (Inflammations) 08/01/2022 - "The aim of this study was to evaluate the potential anti-inflammatory and anti-resorptive effects of lenabasum in the context of Porphyromonas gingivalis (Pg)-induced inflammation. " 08/01/2022 - "Lenabasum showed promising anti-inflammatory and pro-resolutive properties in the management of Pg-elicited inflammation, and thus, its potential as adjuvant periodontal treatment should be further investigated." 08/01/2022 - "Lenabasum Reduces Porphyromonas gingivalis-Driven Inflammation." 01/01/2021 - "Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum." 01/01/2020 - "In CF macrophages lenabasum modulates macrophage polarization and function in vitro in a way that would reduce inflammation in vivo. "

Related Drugs and Biologics

1.	Cannabinoids
2.	HU 211 (HU 210)
3.	Cannabidiol
4.	Cannabinoid Receptors (Cannabinoid Receptor)
5.	lenabasum (ajulemic acid)
6.	Acids
7.	Cannabinoid Receptor Agonists
8.	Dronabinol (THC)
9.	Eicosanoids
10.	Analgesics (Analgesic Drugs)

Related Therapies and Procedures

1.	Oral Administration